Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study.

Background: Recombinant human growth hormone has been used for more than 30 years and its indications have increased worldwide. There is concern that this treatment might increase mortality, but published data are scarce. We present data from the entire dataset of all eight countries of the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) consortium, with the aim of studying long-term overall and cause-specific mortality in young adult patients treated with recombinant human growth hormone during childhood and relating this to the underlying diagnosis.

Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone.

Background: The long-term safety of growth hormone treatment is uncertain. Raised risks of death and certain cancers have been reported inconsistently, based on limited data or short-term follow-up by pharmaceutical companies.

Patients And Methods: The SAGhE (Safety and Appropriateness of Growth Hormone Treatments in Europe) study assembled cohorts of patients treated in childhood with recombinant human growth hormone (r-hGH) in 8 European countries since the first use of this treatment in 1984 and followed them for cause-specific mortality and cancer incidence.

Growth hormone treatment for childhood short stature and risk of stroke in early adulthood.

Objectives: We investigated the incidence of stroke and stroke subtypes in a population-based cohort of patients in France treated with growth hormone (GH) for short stature in childhood.

Methods: Adult morbidity data were obtained in 2008-2010 for 6,874 children with idiopathic isolated GH deficiency or short stature who started GH treatment between 1985 and 1996. Cerebrovascular events were validated using medical reports and imaging data and classified according to standard definitions of subarachnoid hemorrhage, intracerebral hemorrhage, and ischemic stroke.

Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study.

Context: Little is known about the long-term health of subjects treated with GH in childhood, and Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) is a study addressing this question.

Objective: The objective of the study was to evaluate the long-term mortality of patients treated with recombinant GH in childhood in France.

Design: This was a population-based cohort study.

Effects of growth hormone therapy in prepubertal children with short stature secondary to intrauterine growth retardation.

A total of 130 short children were included in a French multicentre study and randomized between a control group (group A) and two groups treated with daily subcutaneous injections of GH at doses of 0.7 IU/kg/week (group B) and 1.4 IU/kg/week (group C) for 2 years.

Growth of short normal children in puberty treated for 3 years with growth hormone alone or in association with gonadotropin-releasing hormone agonist.

GH, 0.1 IU/kg/day 6 days/week, was given to 30 early pubertal short patients for 3 years. There were 16 males, aged 14.

Near normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency.

Ten prepubertal children with stature at or below the 1st percentile for height and without growth hormone deficiency received 0.3 U recombinant growth hormone per kilogram daily for 2 years before puberty. Their growth velocity increased from 4 +/- 0.

Three-year results of treatment with growth hormone, alone or associated with oxandrolone, in girls with Turner syndrome. The Kabi Collaborative Study Group.

22 girls with Turner syndrome aged 10.8 +/- 2.4 years with bone age 8.

Modification of 24-hour growth hormone secretion after continuous subcutaneous infusion of growth hormone-releasing hormone (GHRH (1-29)NH2) in short children with low 24-hour growth hormone secretion.

Six short children with low 24-hour growth hormone (GH) secretion were treated with continuous subcutaneous infusion of GHRH (1-29)NH2 for 3 weeks using a portable infusion pump. Restoration of pulsatile GH secretion was observed in all three children treated with 40 micrograms/kg/day of GHRH, but in only one of the three children treated with 20 micrograms/kg/day. All parameters of 24-hour GH secretion increased, but in five children the magnitude of the GH response was greater on day 1 than on day 21 of GHRH treatment.

Insulin pump therapy in young children with type 1 diabetes.

Six 17- to 53-month-old diabetic children had marked metabolic instability characterized by chronic hyperglycemia and frequent or severe hypoglycemia with conventional management that included twice daily insulin injections, diet, and home blood glucose monitoring. Because of the metabolic instability, all were given continuous subcutaneous insulin infusions (CSII) via portable externally worn infusion pump. During 6 months of CSII, there was marked improvement: hemoglobin A1 decreased from 192% +/- 8% (SD) to 152% +/- 31% of the normal mean (P less than 0.

[Early treatment of congenital hypoplasia of the penis with intramuscular delayed-action testosterone].

Three intramuscular injections of 25 to 50 mg of testosterone hexahydrobenzoate were prescribed in 37 boys who presented with hypoplastic penis: 16 with micropenis and normally placed urethra, 21 with hypospadias. Ages ranged from 4 months to 9 years. In almost all children treated between the ages of 6 and 18 months, penis growth became normal for age.

[Thyroid pathology of newborn infants of mothers with Basedow's disease].

Of 15 neonates born to mothers presenting with Graves' disease, who were admitted for presumptive thyroid disorder, 6 presented with neonatal thyrotoxicosis, 4 with goiter and/or hypothyroidism, and 5 presented with euthyroidism. In cases with thyrotoxicosis, the mothers were not or insufficiently treated. Evolution was regressive in 5 instances, there was a craniostenosis and persisting hyperthyroidism in one case.

[Ambulatory treatment of diabetes in children by continuous subcutaneous infusion of insulin using a portable pump].

Six diabetic children, aged 2 to 4 years, were selected for continuous subcutaneous insulin infusion (SCII) therapy using a portable pump, because of unstable glycemic control. Under previous conventional insulin therapy, they experienced both chronic hyperglycemia (mean: 2.10 +/- 0.

Hyporeninemic hypoaldosteronism in infancy: a familial disease.

Hyporeninemic hypoaldosteronism was found in two male siblings with urinary salt wasting and low plasma sodium levels. The eldest, aged 1 yr, had growth retardation, with hyponatremia and normal plasma potassium levels. The second, aged 2 months, had low plasma sodium and high plasma potassium levels.

[Neonatal Basedow's disease with premature craniosynostosis and stenosis of the aqueduct of Sylvius].

Newborn from mother with untreated Graves' disease, born with thyrotoxicosis and exophthalmia, treated with carbimazole from age 6 weeks. At age 8 months, persisting hyperthyroidism requiring the continuation of treatment, and premature craniosynostosis with dilatation of cerebral ventricles suggesting a stenosis of the aqueduct of Sylvius.

[Isolated breast prematurity in young girls].

The clinical and follow-up data of the isolated premature thelarche are reviewed in a series of 61 girls aged 6 months to 6 years. Transitory increase of plasma estrogens was observed in some cases. The results of LHRH test were similar to those from normal girls of the same age.